Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.

Blood advances

Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM.
PMID: 29296835
Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.

Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical impact of mutation load and an effector T-cell...

Cite
Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017;1(22):1884-1890doi: 10.1182/bloodadvances.2016000786.
Bolen, C. R., McCord, R., Huet, S., Frampton, G. M., Bourgon, R., Jardin, F., Dartigues, P., Punnoose, E. A., Szafer-Glusman, E., Xerri, L., Sujobert, P., Salles, G., & Venstrom, J. M. (2017). Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood advances, 1(22), 1884-1890. https://doi.org/10.1182/bloodadvances.2016000786
Bolen, Christopher R, et al. "Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets." Blood advances vol. 1,22 (2017): 1884-1890. doi: https://doi.org/10.1182/bloodadvances.2016000786
Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10. PMID: 29296835; PMCID: PMC5728140.
Copy Download .nbib Format: NLM
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS.
PMID: 34618601
J Clin Oncol. 2021 Dec 01;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 07.

PURPOSE: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL).METHODS: Previously untreated CLL patients age < 70 years received...

Cite
Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021;39(34):3853-3865doi: 10.1200/JCO.21.00807.
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, C., Jacobs, R., Pagel, J. M., Flinn, I., Pak, Y., Zhou, C., Szafer-Glusman, E., Ninomoto, J., Dean, J. P., James, D. F., Ghia, P., & Tam, C. S. (2021). Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(34), 3853-3865. https://doi.org/10.1200/JCO.21.00807
Wierda, William G, et al. "Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,34 (2021): 3853-3865. doi: https://doi.org/10.1200/JCO.21.00807
Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Dec 01;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 07. PMID: 34618601.
Copy Download .nbib Format: NLM
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.

Clinical lymphoma, myeloma & leukemia

Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, Salles GA, Sehn LH, Seymour JF, Trnĕný M, Oestergaard MZ, Mundt KE, Vitolo U.
PMID: 33303421
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):267-278.e10. doi: 10.1016/j.clml.2020.11.004. Epub 2020 Nov 10.

INTRODUCTION: The prognostic value of B-cell lymphoma 2 (BCL2) expression in de novo diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy is of interest to define a target patient population for clinical development of BCL2 inhibitors. We aimed to...

Cite
Punnoose E, Peale FV, Szafer-Glusman E, et al. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clin Lymphoma Myeloma Leuk. 2020;21(4):267-278.e10doi: 10.1016/j.clml.2020.11.004.
Punnoose, E., Peale, F. V., Szafer-Glusman, E., Lei, G., Bourgon, R., Do, A. D., Kim, E., Zhang, L., Farinha, P., Gascoyne, R. D., Munoz, F. J., Martelli, M., Mottok, A., Salles, G. A., Sehn, L. H., Seymour, J. F., Trnĕný, M., Oestergaard, M. Z., Mundt, K. E., & Vitolo, U. (2021). BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clinical lymphoma, myeloma & leukemia, 21(4), 267-278.e10. https://doi.org/10.1016/j.clml.2020.11.004
Punnoose, Elizabeth, et al. "BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis." Clinical lymphoma, myeloma & leukemia vol. 21,4 (2021): 267-278.e10. doi: https://doi.org/10.1016/j.clml.2020.11.004
Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, Salles GA, Sehn LH, Seymour JF, Trnĕný M, Oestergaard MZ, Mundt KE, Vitolo U. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):267-278.e10. doi: 10.1016/j.clml.2020.11.004. Epub 2020 Nov 10. PMID: 33303421.
Copy Download .nbib Format: NLM
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS.
PMID: 34618601
J Clin Oncol. 2021 Dec 01;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 07.

PURPOSE: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL).METHODS: Previously untreated CLL patients age < 70 years received...

Cite
Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021;39(34):3853-3865doi: 10.1200/JCO.21.00807.
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, C., Jacobs, R., Pagel, J. M., Flinn, I., Pak, Y., Zhou, C., Szafer-Glusman, E., Ninomoto, J., Dean, J. P., James, D. F., Ghia, P., & Tam, C. S. (2021). Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(34), 3853-3865. https://doi.org/10.1200/JCO.21.00807
Wierda, William G, et al. "Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,34 (2021): 3853-3865. doi: https://doi.org/10.1200/JCO.21.00807
Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Dec 01;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 07. PMID: 34618601.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries